Nicole Germino
Stock Analyst at Truist Securities
(2.31)
# 2,538
Out of 4,711 analysts
18
Total ratings
40%
Success rate
3.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Buy | $100 → $105 | $70.44 | +49.06% | 7 | Nov 1, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $21 | $2.85 | +636.84% | 1 | Sep 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $21 | $8.28 | +153.62% | 1 | Jun 28, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Hold | n/a | $2.47 | - | 4 | Nov 7, 2023 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $15.21 | +57.79% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $19.34 | - | 2 | Sep 3, 2021 |
Insmed
Nov 1, 2024
Reiterates: Buy
Price Target: $100 → $105
Current: $70.44
Upside: +49.06%
Perspective Therapeutics
Sep 25, 2024
Initiates: Buy
Price Target: $21
Current: $2.85
Upside: +636.84%
Y-mAbs Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $21
Current: $8.28
Upside: +153.62%
Sangamo Therapeutics
Nov 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.47
Upside: -
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $15.21
Upside: +57.79%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $19.34
Upside: -